Prescient Therapeutics targets $7 million raise to advance PTX-100 cancer program
August 25, 2026
Latest announcements
Announcement type:
Search Announcements 
Sensitive
Year:
| Price Sensitive |
Latest announcements
Announcement type:
Search Announcements
Sensitive
Year:
| Price Sensitive |
About Prescient Therapeutics
Prescient Therapeutics develops targeted therapies to treat cancer. It has a broad portfolio of well advanced assets developed with world-leading partners including Yale, UPenn, Oxford, Moffitt & Peter MacCallum.
Prescient’s first in class targeted therapy – PTX-100 – is currently in Phase 2a clinical development and has previously demonstrated significant results in diseases of unmet need with key FDA designation, including Orphan Drug and Fast Track.
Prescient also owns the exclusive rights to two next generation cell therapy platform technologies, OmniCAR and CellPryme – both with the potential to enhance cell therapies and overcome challenges faced by current generation approaches.
8th April, 2022
Watch this 5-minute video to hear from CEO Michael Davidson to learn more about:
- How they are moving forward one of the most advanced cancer therapies on the ASX.
- Why the FDA has fast tracked PTX-100.
- Furthermore, how their platform technology could apply to 22% of all cancer cases worldwide.
To stay up to date with Prescient Therapeutics or to receive alerts on company events, please register your details.
Our board
Board
Management
‹
Dr James Campbell
Non-Executive Chair
Dr James Campbell
Non-Executive Chair
Dr James Campbell brings to Prescient a solid track record as a scientist and commercial executive. Dr. Campbell has more than 25 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies. He is currently Chair of AusBiotech, Australias peak biotechnology industry association, and was formerly CEO of Patrys Limited, a company that developed novel antibody therapeutics for oncology. He was previously the Chief Financial Officer and Chief Operating Officer of Chemgenex, which was acquired by Cephalon for $230 million in 2011. His responsibilities ranged from IP management to licensing and business development and as a member of the executive team, he helped steer and transform the company from a $10 million research based entity to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA before its $230 million sale. Dr Campbell also has experience advising private biotechnology companies in the US and New Zealand with capital raisings and partnering negotiations.
Dr Allen Ebens
Non-Executive Director
Dr Allen Ebens
Non-Executive Director
Allen Ebens, Ph.D. brings over twenty four years of drug development experience in oncology and hematology, beginning in drug discovery at Exelixis before moving to Genentech where over 11 years he worked from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, antibody-drug conjugates, and T cell recruiting antibodies.
Dr. Ebens was recruited from Genentech to establish oncology discovery research at Juno Therapeutics (a CAR-T pioneer), and served as Senior Director, Immune Oncology at NGM Biopharmaceuticals.
He is currently Chief Scientific Officer of Vera Therapeutics. Dr. Ebens’ scientific contributions include numerous peer-reviewed publications of original research, a significant patent portfolio, and the advancement of nine discovery projects from initial concept to clinical development for multiple targets including one marketed therapeutic. He completed his PhD at UCLA and postdoctoral training at UCSF.
Dr Ellen Feigal
Non-Executive Director
Dr Ellen Feigal
Non-Executive Director
Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. She is also adjunct faculty at the Sandra Day O’Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law.
Dr Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, a world-leading research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc (NASDAQ: AMGN); Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute.
Dr Feigal serves as a Board member for Xencor Inc (NASDAQ: XNCR) a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a Director of NextCure (NASDAQ: NXTC) a clinical-stage biotechnology company developing new immunotherapies to treat cancer.
Dr Feigal holds an M.D. from the University of California, Davis School of Medicine. She completed an internal medicine residency at Stanford University and a hematology oncology fellowship at the University of California, San Francisco.
Dr Gavin Shepherd
Non-Executive Director
Dr Gavin Shepherd
Non-Executive Director
Dr Shepherd is an accomplished medical professional with 25 years of experience in medicine and a proven track record in driving success in various specialist consulting businesses. After completing his medical qualification at Flinders University, he completed specialist training as a consultant Occupational and Environmental Physician with a fellowship from the Royal Australasian College of Physicians. He graduated dux of his Graduate Diploma in OH+S at Adelaide University and he completed his GAICD qualification in 2011. He is a serial Australian biotech investor and a non-executive director of Lateral Pharma Pty Ltd.
Melanie Leydin
Company Secretary
Melanie Leydin
Company Secretary
Melanie Leydin is a highly experienced CFO and Company Secretary with 25 years of experience in the accounting profession and 15 years of experience in company secretarial services
Melanie Farris
Non-Executive Director
Melanie Farris
Non-Executive Director
Ms Farris is an experienced non-executive director, governance, risk and communications professional in the listed, public and not-for-profit sectors, possessing a strong track record in the planning, delivery and oversight of strategic corporate, funding, governance and risk projects across industries including life sciences, investment, agriculture, not-for-profit and music industry marketing.
With extensive senior executive tenure including as chief governance and risk officer, chief financial officer, chief operating officer, group company secretary, senior risk and sustainability advisor, prior roles include with Telix Pharmaceuticals Limited (ASX: TLX), Factor Therapeutics Limited (ASX: FTT), Invion Limited (ASX: IVX), Menzies Research Centre, HRH The Prince of Wales’s Office, Global Asset Management, Imperial Cancer Research Fund, and The Prince’s Foundation.
Melanie holds a Bachelor of Communication (Public Relations), and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors.
›
‹
Said Sebti, PhD
Scientific Founder
Said Sebti, PhD
Scientific Founder
- Co-inventor of PTX-100 & PTX-200
- Named among top 20 Translational Researchers in the world by Nature Publishing Group
Terry Chew, M.D.
Executive Advisor Clinical and Regulatory
Terry Chew, M.D.
Executive Advisor Clinical and Regulatory
- Hematologist/oncologist with 20 years experience in biotech & pharma
- 5 New Drug Applications including DaunoXome, Taxotere and DepoCyte
Tracey Owens PHD
CMC Project Manager
Tracey Owens PHD
CMC Project Manager
- Experience in project management of drug substance, including synthesis, method development and qualification
- Formerly Sterling Pharma Solutions and Thermo Fisher Scientific
- PhD in chemical biology
Luis Malaver-Ortega, PhD
Director Research and Development
Luis Malaver-Ortega, PhD
Director Research and Development
- Over 10 years of experience in biomedical R&D gained through appointments at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), the Australian Institute for Bioengineering and Nanotechnology (AIBN), Me&Biotech, the Melbourne Centre for Nanofabrication (MCN), and The Hudson Institute of Medical Research.
- Technical expertise in cell line development, genome editing, functional genomics, and bioprocessing.
- Co-author and inventor in several scientific articles and patents in biotechnology and cancer research.
Upaly Bahadure
Director – Clinical Affairs & Operations
Upaly Bahadure
Director – Clinical Affairs & Operations
- Over 17 years of experience in clinical development, driving programs from pre-clinical development through to regulatory submissions and successful commercialisation
- Experience in leading global studies in oncology, including immuno-oncology
- Formerly Beigene Global Clinical Program Lead
- CRO experience with Chiltern International; Quintiles Research
- Background in Pharmacy and Pharmaceutical Marketing
Dr Rosalind Wilson
Chief Medical Officer
Dr Rosalind Wilson
Chief Medical Officer
Highly accomplished pharmaceutical and biotechnology executive.
More than 30 years of experience spanning clinical development, regulatory strategy and executive leadership.
Served as Global Head of Drug Development at Telix Pharmaceuticals, CEO of ASX-listed Factor Therapeutics, as well as the CMO to several oncology-focused biotechnology companies.
Proven track record advancing therapies from early development through to approval and launch.
James McDonnell
CEO
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company’s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
Dr Rebecca Tunstall
Chief Operating Officer
Dr Rebecca Tunstall
Chief Operating Officer
Dr Rebecca Tunstall is a highly accomplished executive in the Australian biotechnology and pharmaceutical sectors, with nearly 20 years of experience in strategy, oncology product development, and operational excellence.
Across her career, Rebecca has held pivotal leadership positions at prominent organisations including GSK, MTPConnect, and Patrys Ltd. At GSK, she built significant value over 13 years in senior oncology roles, developing deep expertise in therapeutic development and commercialisation. As Senior Director of Stakeholder Engagement at MTPConnect, she orchestrated collaborative initiatives connecting Australia’s medtech and biotech ecosystem with industry and government partners. Most recently, Rebecca served as Vice President of Corporate Development at Patrys Ltd (ASX:PAB), where she executed critical business development and cross-functional initiatives.
Rebecca holds a PhD and Bachelor of Applied Science with Honours, and is a graduate of the Australian Institute of Company Directors.
›
Live Investor Briefing
Prescient Therapeutics (ASX: PTX)
Friday 28th August, 1pm (AEST) & Thursday 3rd September, 12pm (AEST)
Please join Prescient Therapeutics CEO James McDonnell for an investor briefing.
In this session, James will discuss:
- The first-in-class cancer therapy PTX -100 – now in Phase 2a clinical trials.
- The potential to make Phase 2b a registration study2, with FDA Fast Track and Orphan Drug Designation secured.
- Why PTX is at a stage where it becomes attractive to large pharmaceutical companies.
This should be a fascinating session about why PTX-100 is one of the most advanced cancer therapies on the ASX1 and their plans for an accelerated commercial pathway after encouraging Phase 1b results3.
Spots are limited, so secure yours today.
Can’t make this time, register to receive the replay.
Attend the Session
What is a 708 investor?By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets who have been engaged by Prescient Therapeutics Limited to provide Corporate Advisory Services, including managing investor communications and may receive fees for its services.
Please join Prescient CEO James McDonnell for an investor briefing.
Receive email updates
By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.
- Based on public data
- Subject to regulatory approvals
- 100% clinical benefit rate and zero serious adverse events that were treatment related. CTCL subgroup, n=7 evaluable patients
